TECHNOLOGY & SECURITY
October 23, 2017
- The U.S Food and Drug Administration issued a CRL to Antares Pharma on the 20th Oct in regard to their drug: XYOSTED.
- Concerns about blood pressure and psychological side effects emerged.
- Here we evaluate possible outcomes.
Guest post by Jennifer Chin. The views and...
October 22, 2017
- Antares Pharma Inc.’s QuickShot Testosterone (XYOSTED) is awaiting Phase 3 approval by the FDA for treatment of low testosterone levels associated with hypogonadism.
- On the 12th of October, the company announced that it had received notice from the FDA which identif...